Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-23T03:35:35.810Z Has data issue: false hasContentIssue false

Chlorogenic acids, sleep architecture and energy metabolism

Published online by Cambridge University Press:  19 March 2018

Tomoyuki Kawada*
Affiliation:
Department of Hygiene and Public Health, Nippon Medical School, Tokyo 113-8602, Japan
Rights & Permissions [Opens in a new window]

Abstract

Type
Letter to the Editor
Copyright
Copyright © The Author 2018 

Park et al. ( Reference Park, Ochiai and Ogata 1 ) conducted a randomised, placebo-controlled, double-blinded cross-over trial to examine the effect of consuming chlorogenic acids (CGA) over 5 d on energy metabolism and sleep quality in humans. They found that the consumption of CGA significantly increased fat oxidation during sleep, and they speculated that it might reduce body fat and prevent obesity. In addition, consumption of CGA enhanced parasympathetic activity, as assessed by heart-rate variability during sleep. However, CGA consumption did not have significant effects on sleep architecture, except for shortened sleep latency. I have some concerns about their study.

First, the authors considered that CGA consumption reduced body fat and body weight. However, a review of the literature yields no clear evidence of a relationship between CGA and these outcomes( Reference Tajik, Tajik and Mack 2 ). In addition, a 5-d-long intervention is not representative of continuous consumption of CGA. The study was too short and there is a lack of causality between CGA and the outcomes. Further study is needed for assessing the consumption of CGA and obesity through a longer follow-up period.

Second, insufficient sleep in people with obesity is a risk factor for metabolic disorders( Reference Schmid, Hallschmid and Schultes 3 ). Unfortunately, this study observed no significant association between consumption of CGA and change in sleep architecture. It is possible that a 5-d intervention period cannot lead to the improvement of sleep architecture. However, sleep latency significantly became shorter. As such, an interventional study using sleep parameters would be useful in understanding the effect of CGA consumption on sleep quality.

Finally, there is a need for speculation regarding the origin of CGA. If the authors considered coffee as the main source of consumption, the association between consumption of CGA and sleep architecture should be considered according to caffeine intake( Reference Hayashi, Masuda and Hori 4 ). That said, a meta-analysis reported that both caffeinated and decaffeinated coffee consumption was associated with reduced risk of diabetes( Reference Ding, Bhupathiraju and Chen 5 ). Inter-relationships among sleep, obesity, metabolic disorders and CGA should be further studied.

Acknowledgements

This research received no specific grant from any funding agency, commercial or not-for-profit sectors.

The author declares that there are no conflicts of interest.

References

1. Park, I, Ochiai, R, Ogata, H, et al. (2017) Effects of subacute ingestion of chlorogenic acids on sleep architecture and energy metabolism through activity of the autonomic nervous system: a randomised, placebo-controlled, double-blinded cross-over trial. Br J Nutr 117, 979984.CrossRefGoogle ScholarPubMed
2. Tajik, N, Tajik, M, Mack, I, et al. (2017) The potential effects of chlorogenic acid, the main phenolic components in coffee, on health: a comprehensive review of the literature. Eur J Nutr 56, 22152244.CrossRefGoogle Scholar
3. Schmid, SM, Hallschmid, M & Schultes, B (2015) The metabolic burden of sleep loss. Lancet Diabetes Endocrinol 3, 5262.Google Scholar
4. Hayashi, M, Masuda, A & Hori, T (2003) The alerting effects of caffeine, bright light and face washing after a short daytime nap. Clin Neurophysiol 114, 22682278.CrossRefGoogle ScholarPubMed
5. Ding, M, Bhupathiraju, SN, Chen, M, et al. (2014) Caffeinated and decaffeinated coffee consumption and risk of type 2 diabetes: a systematic review and a dose–response meta-analysis. Diabetes Care 37, 569586.CrossRefGoogle Scholar